% | $
Quotes you view appear here for quick access.

Thoratec Corporation Message Board

  • professor4everyone professor4everyone Feb 5, 2013 6:27 PM Flag

    In Conclusion The H/MVAD 160mg To 325 mg Aspirin Dose Is Still A device-killer

    The Simple HM3 MagLev technology is far superior to the H/MVAD overly complex blood-flow technology and allows much further efficacy and cost reduction.

    The FILVAS fully implantable technology is having great success in testing and should eliminate Heart Transplants. The Bionic Man has arrived.

    THOR will fully dominate the HUGE multi-BILLION$$$ Heart Failure market in both implants and in the Acute Catheter Lab.

    Meanwhile THOR's Free-Cash-Flow is outstanding and will continue to sharply reduce share count with continuous buy-backs. And they have ZERO DEBT!!!!

    SortNewest  |  Oldest  |  Most Replied Expand all replies
63.500.00(0.00%)Oct 8 4:00 PMEDT